257 related articles for article (PubMed ID: 24065124)
1. Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
Aizawa N; Enomoto H; Takashima T; Sakai Y; Iwata K; Ikeda N; Tanaka H; Iwata Y; Saito M; Imanishi H; Iijima H; Nishiguchi S
J Gastroenterol; 2014 Aug; 49(8):1253-63. PubMed ID: 24065124
[TBL] [Abstract][Full Text] [Related]
2. Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype.
Motomura T; Shirabe K; Furusyo N; Yoshizumi T; Ikegami T; Soejima Y; Akahoshi T; Tomikawa M; Fukuhara T; Hayashi J; Maehara Y
BMC Gastroenterol; 2012 Nov; 12():158. PubMed ID: 23145809
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy of low-dose of PegIFNa-2a and ribavirin for patients with HCV-infected decompensated cirrhosis.
Sun Y; Chang B; Teng G; Zhang W; Zhao J; Li B
Hepatogastroenterology; 2013 Sep; 60(126):1391-8. PubMed ID: 23635509
[TBL] [Abstract][Full Text] [Related]
4. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
[TBL] [Abstract][Full Text] [Related]
5. Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization.
Foruny JR; Blázquez J; Moreno A; Bárcena R; Gil-Grande L; Quereda C; Pérez-Elías MJ; Moreno J; Sánchez J; Muriel A; Rodriguez-Sagrado MA; Moreno S
Eur J Gastroenterol Hepatol; 2005 Nov; 17(11):1157-64. PubMed ID: 16215426
[TBL] [Abstract][Full Text] [Related]
6. Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.
Tamai H; Mori Y; Shingaki N; Kawashima A; Tsukuda H; Higashi K; Moribata K; Kawaguchi M; Ueda K; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M
Antivir Ther; 2014; 19(1):107-15. PubMed ID: 24162072
[TBL] [Abstract][Full Text] [Related]
7. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
[TBL] [Abstract][Full Text] [Related]
8. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
[TBL] [Abstract][Full Text] [Related]
10. Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.
Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Okada K; Kainuma M; Kajiwara E; Takahashi K; Satoh T; Hayashi J
J Viral Hepat; 2013 Dec; 20(12):838-46. PubMed ID: 24304453
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C.
Kondo C; Atsukawa M; Tsubota A; Shimada N; Abe H; Itokawa N; Nakagawa A; Fukuda T; Matsushita Y; Nakatsuka K; Kawamoto C; Iwakiri K; Aizawa Y; Sakamoto C
Intern Med; 2015; 54(2):119-26. PubMed ID: 25743001
[TBL] [Abstract][Full Text] [Related]
12. Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.
Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Iio S; Oshita M; Hagiwara H; Mita E; Inui Y; Hijioka T; Inada M; Tamura S; Yoshihara H; Inoue A; Imai Y; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Hayashi N; Takehara T
J Gastroenterol; 2014 Apr; 49(4):737-47. PubMed ID: 23689988
[TBL] [Abstract][Full Text] [Related]
13. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.
Kim SR; El-Shamy A; Imoto S; Kim KI; Ide YH; Deng L; Shoji I; Tanaka Y; Hasegawa Y; Ota M; Hotta H
J Gastroenterol; 2012 Oct; 47(10):1143-51. PubMed ID: 22441534
[TBL] [Abstract][Full Text] [Related]
14. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.
Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
Liver Int; 2011 Oct; 31(9):1359-65. PubMed ID: 21745312
[TBL] [Abstract][Full Text] [Related]
15. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
Tohra SK; Taneja S; Ghosh S; Sharma BK; Duseja A; Dhiman RK; Das A; Chawla YK
Dig Dis Sci; 2011 Aug; 56(8):2449-55. PubMed ID: 21706207
[TBL] [Abstract][Full Text] [Related]
16. Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study.
Nishiguchi S; Enomoto H; Aizawa N; Nishikawa H; Osaki Y; Tsuda Y; Higuchi K; Okazaki K; Seki T; Kim SR; Hongo Y; Jyomura H; Nishida N; Kudo M
J Gastroenterol; 2014 Mar; 49(3):492-501. PubMed ID: 23543311
[TBL] [Abstract][Full Text] [Related]
17. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
Tahata Y; Hiramatsu N; Oze T; Urabe A; Morishita N; Yamada R; Yakushijin T; Hosui A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Yamada Y; Inada M; Katayama K; Tamura S; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
J Med Virol; 2016 Oct; 88(10):1776-84. PubMed ID: 26991414
[TBL] [Abstract][Full Text] [Related]
18. A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia.
Tahara H; Takagi H; Sato K; Shimada Y; Tojima H; Hirokawa T; Ohyama T; Horiuchi K; Naganuma A; Arai H; Kakizaki S; Mori M
J Gastroenterol; 2011 Aug; 46(8):1010-9. PubMed ID: 21594564
[TBL] [Abstract][Full Text] [Related]
19. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
[TBL] [Abstract][Full Text] [Related]
20. Pegylated interferon α-2a plus ribavirin for decompensated hepatitis C virus-related cirrhosis: relationship between efficacy and cumulative dose.
Xu Y; Qi W; Wang X; Zhao P; Zhang Y; Zhang Q; Qin S; Wang J
Liver Int; 2014 Nov; 34(10):1522-31. PubMed ID: 25453135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]